EGFR and neoplasm: Accordingly, the relative risk (RR) to show PD in the first staging after starting with ICI was 1.99 for cases in which the tumor harbors a mutation in EGFR, PTEN or TP53 or the patient was pretreated with BRAF/MEKi.